Journal article

Global update on the susceptibilities of human influenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2017-2018

Emi Takashita, Rod S Daniels, Seiichiro Fujisaki, Vicki Gregory, Larisa Gubareva, Weiijuan Huang, Aeron C Hurt, Angie Lackenby, Ha T Nguyen, Dmitriy Pereyaslov, Merryn Roe, Magdi Samaan, Kanta Subbarao, Herman Tse, Dayan Wang, Hui-Ling Yen, Wenqing Zhang, Adam Meijer

ANTIVIRAL RESEARCH | ELSEVIER | Published : 2020

Abstract

The global analysis of neuraminidase inhibitor (NAI) susceptibility of influenza viruses has been conducted since the 2012-13 period. In 2018 a novel cap-dependent endonuclease inhibitor, baloxavir, that targets polymerase acidic subunit (PA) was approved for the treatment of influenza virus infection in Japan and the United States. For this annual report, the susceptibilities of influenza viruses to NAIs and baloxavir were analyzed. A total of 15409 viruses, collected by World Health Organization (WHO) recognized National Influenza Centers and other laboratories between May 2017 and May 2018, were assessed for phenotypic NAI susceptibility by five WHO Collaborating Centers (CCs). The 50% in..

View full abstract

Grants

Awarded by Advanced Molecular Detection (AMD) Program, CDC


Awarded by National Key Research and Development Program of China


Awarded by Francis Crick Institute from Cancer Research UK


Awarded by Francis Crick Institute from Medical Research Council


Awarded by Francis Crick Institute from Wellcome Trust


Awarded by Ministry of Health, Labour and Welfare, Japan


Awarded by JSPS KAKENHI


Funding Acknowledgements

The Atlanta CC received grants [#AMD-77 and #AMD-102] from the Advanced Molecular Detection (AMD) Program, CDC, to establish the next generation sequencing and bioinformatics support for influenza viruses. The Beijing CC received grants from National Key Research and Development Program of China [2016YFD0500208]. The London CC is supported by the Francis Crick Institute receiving core funding from Cancer Research UK [FC001030], the Medical Research Council [FC001030] and the Wellcome Trust [FC001030]. The Melbourne CC is supported by the Australian Government, Department of Health. The Tokyo CC is supported by Grants-in-Aid for Emerging and Re-emerging Infectious Diseases from the Ministry of Health, Labour and Welfare, Japan [10110400] and by JSPS KAKENHI Grant number 18K10036.